Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.

Lewiecki, E Michael; Dinavahi, Rajani V; Lazaretti-Castro, Marise; Ebeling, Peter R; Adachi, Jonathan D; Miyauchi, Akimitsu; Gielen, Evelien; Milmont, Cassandra E; Libanati, Cesar; Grauer, Andreas

Journal Of Bone And Mineral Research

Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.

Author:

Lewiecki, E Michael

Dinavahi, Rajani V ; Lazaretti-Castro, Marise ; Ebeling, Peter R ; Adachi, Jonathan D ; Miyauchi, Akimitsu ; Gielen, Evelien ; Milmont, Cassandra E ; Libanati, Cesar ; Grauer, Andreas

Keywords:

Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, 06 Biological Sciences, 09 Engineering, 11 Medical and Health Sciences, Anatomy & Morphology, 31 Biological sciences, 32 Biomedical and clinical sciences

Journal Of Bone And Mineral Research Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.

Author:

Keywords:

Journal Of Bone And Mineral Research

Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.